NCT01217203View on ClinicalTrials.gov

Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

December 31, 2013

Study Completion Date

February 28, 2014

Conditions
Patients With Multiple Myeloma Experiencing aFirst or Second Relapse
Interventions
DRUG

IPH2101 combined to lenalidomide

"Dose level 1 : 0.2 mg/kg IPH2101(with Lenalidomide 10 mg/day) Dose level 2 : 0.2 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 3 : 1 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 4 : 2 mg/kg IPH2101(with Lenalidomide 25 mg/day)~Extension cohort: 6 patients at the Maximum Tolerated Dose (MTD)"

Trial Locations (6)

10016

NYU Clinical Cancer Center, New York

10029

Mount Sinai Medical Center, New York

19111

Fox Chase Cancer Center, Philadelphia

29601

Saint Francis Hospital, Greensville

43210

The Ohio State University Comprehensive Cancer Center, Columbus

02115

Dana Farber, Boston

Sponsors

Lead Sponsor

Innate Pharma
All Listed Sponsors
lead

Innate Pharma

INDUSTRY

NCT01217203 - Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse | Biotech Hunter | Biotech Hunter